Research programme: familial amyloidotic polyneuropathy RNAi therapy - BIOALVO

Drug Profile

Research programme: familial amyloidotic polyneuropathy RNAi therapy - BIOALVO

Alternative Names: TTR Silencer

Latest Information Update: 17 Feb 2011

Price : $50

At a glance

  • Originator BIOALVO
  • Class Small interfering RNA
  • Mechanism of Action RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Amyloid polyneuropathy

Most Recent Events

  • 26 Feb 2007 Preclinical development is ongoing
  • 29 Aug 2005 Preclinical trials in Amyloid polyneuropathy in Portugal (unspecified route)
  • 29 Aug 2005 Potential therapeutics from this programme will be available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top